Kenneth Ssebambulidde Ssebambulidde
ID: UNCST-2021-R013976
|
Relationship between maternal or newborn cholesterol levels and neonatal septicaemia: A Ugandan cohort of mother-new-born pairs
REFNo: HS1204ES
Primary objective: To elucidate a relationship between maternal and neonatal cholesterol levels and neonatal septicaemia
Secondary objectives:
1. To determine whether abnormal maternal cholesterol levels are associated with a risk for neonatal septicaemia.
2. To describe the correlation between maternal cholesterol levels and cord blood neonatal cholesterol levels at birth.
3. To determine the association between cord blood cholesterol levels and neonatal septicaemia
|
Uganda |
2021-08-11 |
2024-08-11 |
Medical and Health Sciences |
|
Non-degree Award |
|
ANTHONY KAYIIRA
ID: UNCST-2020-R014108
|
Prognostic value of serum hCG-β level, 12 days after embryo transfer, on predicting live birth among Ugandan women.
REFNo: HS1569ES
4. To determine the sensitivity and specificity of serum hCG-β level cut offs, 12 days after embryo transfer, on predicting pregnancy loss,3. To determine the sensitivity and specificity of serum hCG-β level cut offs, 12 days after embryo transfer, on predicting clinical pregnancy ,2. To determine the sensitivity and specificity of serum hCG-β level cut offs, 12 days after embryo transfer, on predicting biochemical pregnancy ,1. To determine the sensitivity and specificity of serum hCG-β level cut offs, 12 days after embryo transfer, on predicting live birth,To evaluate the prognostic value of serum hCG-β level cut off, 12 days after embryo transfer, on predicting pregnancy outcome among Ugandan women following an IVF-ET cycle.,
|
Uganda |
2021-08-11 |
2024-08-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Abel Atukwase
ID:
|
EXPOSURE ASSESSMENT AND ANALYSIS OF HEALTH RISKS ASSOCIATED WITH CONSUMPTION OF AFLATOXIN CONTAMINATED STAPLES IN UGANDA
REFNo: A132ES
The overall objective of the project is to generate information that will guide the development of evidence-based policies and strategies for management of health risks associated with aflatoxins in Uganda. The specific objectives are to;
1. Determine the levels of aflatoxins in maize, sorghum and groundnuts produced and consumed in Uganda
2. Assess aflatoxin exposure among children (6-59 months) and women of reproductive age (15-49 years)
3. Characterise the health risks associated with consumption of maize, sorghum and groundnuts among children 6-59 months and women of reproductive age (15-49 years)
4. Develop policy briefs aimed at improving awareness amongst policy makers and stimulate formulation of policies and strategies for mitigating aflatoxin associated health risks.
|
Uganda |
2021-08-11 |
2024-08-11 |
Agricultural Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Maxensia owor
ID: UNCST-2021-R014003
|
IMPAACT 2017: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. Version 3.0, dated 13 August 2020
REFNo: HS1356ES
Primary Objectives:
Cohort 1
1.To confirm the doses for oral CAB followed by injectable CAB LA in HIV-infected, virologically suppressed adolescents
2.To confirm doses for injectable RPV LA in HIV-infected, virologically suppressed adolescents by evaluating safety and multiple dose PK of RPV LA through Week 16
Cohort 2:
1.To assess the safety of CAB LA + RPV LA through Week 24 in HIV-infected, virologically suppressed adolescents
Secondary Objectives: Cohort 1
• To monitor maintenance of viral suppression through Week 16 in HIV-infected, virologically suppressed adolescents
• To evaluate the tolerability and acceptability of CAB LA through Week 16 in HIV-infected,virologically suppressed adolescents
• To evaluate the tolerability and acceptability of RPV LA through Week 16 in HIV-infected,virologically suppressed adolescents
Secondary Objectives: Cohort 2
• To assess safety of oral CAB + oral RPV followed by CAB LA + RPV LA through Week 48 in HIVinfected, virologically suppressed adolescents
• To evaluate repeat-dose pharmacokinetics of CAB LA + RPV LA through Week 24, and through
Week 48 in HIV-infected, virologically suppressed adolescents.
• To assess antiviral activity of CAB LA + RPV
|
Uganda |
2021-08-11 |
2024-08-11 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
John Gitta Kavuma
ID:
|
Corporate Governance and Christian Organisational Culture in
Anglican Church Founded Universities in Uganda
REFNo: SS794ES
1-To analyse the effect of corporate governance on university policies in Ndejje and UCU.
2-To assess the relationship between governing Policies and Christian values at Ndejje and UCU
3-To evaluate the influence of Christian values on organizational culture of Ndejje and UCU.
4-To compute the contribution of Corporate Governance on promoting Christian
organizational culture.
|
Uganda |
2021-08-11 |
2024-08-11 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Jimmy, Maguru Mugisha Maguru
ID:
|
The ‘unexpected visitors’ and ‘good-host’ discourse: Social Accountability, Policy and Realities of Sexual and Reproductive Health of young people in two refugee settlements in Uganda
REFNo: SS828ES
1. To examine governance and accountability mechanisms of sexual and reproductive
health service delivery of the young refugees in refugee settlements in Uganda.
2. To examine the role of young refugees in the governance mechanisms of SRH and the
accountability chain and how this influences their ability to voice and to access SRH
services in refugee settings
3. To explore the challenges faced by young refugees and their coping mechanisms in
accessing and utilizing the ASRH services in refugee settlements in Uganda.
|
Uganda |
2021-08-11 |
2024-08-11 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Violet Nakibuuka
ID: UNCST-2021-R003675
|
PREVALENCE AND FACTORS ASSOCIATED WITH HUMAN PAPILLOMA VIRUS VACCINATION AMONG ADOLESCENTS GIRLS AGED 9 TO 19 YEARS LIVING WITH HIV AT MULAGO ISS CLINIC, KAMPALA, UGANDA
REFNo: HS1436ES
1. To determine the prevalence of HPV vaccination among HIV positive adolescent girls aged 9-19 years at Mulago ISS Clinic, Kampala, Uganda.
2. To determine the factors associated with HPV vaccination among HIV positive adolescent girls aged 9-19 years at Mulago ISS Clinic Kampala, Uganda
3. To explore the perspectives, perceptions and experiences of healthcare providers, adolescent girls and their care takers at Mulago ISS Clinic regardingHPV vaccination among HIV positive adolescent girls.
|
Uganda |
2021-08-11 |
2024-08-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Derry Taylor James
ID:
|
Learned social knowledge in chimpanzees
REFNo: NS269ES
To understand the nature of chimpanzee social knowledge and how it is acquired
|
UK |
2021-08-11 |
2024-08-11 |
Natural Sciences |
Non-Clinical Trial |
Non-degree Award |
|
MOSES EGESA
ID: UNCST-2025-R015361
|
Epitope mapping of schistosome tegument and alimentary tract proteins in humans
REFNo: HS1463ES
1. To determine the change in antibody reactivity profile of individuals of an endemic area to epitopes of tegument and alimentary tract proteins before and after PZQ treatment
2. To identify antibody reactivity to epitopes putatively associated with protection against reinfection
|
Uganda |
2021-08-11 |
2024-08-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Pontiano Kaleebu
ID: UNCST-2020-R019901
|
Field Performance Evaluation of the m-PIMAâ„¢ HIV-1/2 VL plasma assay in Uganda
REFNo: HS1606ES
Main objective
To evaluate the field performance of the m-PIMATM HIV-1/2 VL plasma VL in identifying virological failure (VF) in adults on ART. The performance will be compared to standard PCR assays used at UNHLs and UVRI.
2.3.2 Primary objectives
I). To evaluate the diagnostic accuracy using the sensitivity, specificity, NPV, PPV, FPR and FNR of the m-PIMAâ„¢ HIV-1/2 VL plasma assay in comparison to a reference assay of HIV-1 RNA PCR in identifying HIV-VF at the WHO recommended threshold of 1000 copies/ml for HIV-1 infected.
II). To determine the operational characteristics of the m-PIMAâ„¢ HIV-1/2 VL plasma assay, such as ease of-use of the assay using the standardized system usability scale (SUS) by laboratory and no laboratory personnel
III). To determine changes in turn-around time and ease of clinic workflow integration.
IV).To determine acceptability of the m-PIMAâ„¢ HIV-1/2 VL plasma assay by the study participants
|
Uganda |
2021-08-11 |
2024-08-11 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|